Semaglutide has reportedly passed a significant test, but the FDA's next steps are unclear. The development of semaglutide and similar drugs, such as GLP-1s, may be impacted by various factors, including clinical trial targets and access to compounded versions. The potential for widespread adoption of semaglutide may depend on factors like pricing, although the outcome is uncertain.